Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 48, Issue 8, 2007, Pages 1482-1495

  Tward, Jonathan ^a   Glenn, Martha ^a   Pulsipher, Michael ^a   Barnette, Phillip ^a   Gaffney, David ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Epidemiology; Non Hodkin lymphoma; Radiation; Secondary malignancies

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DNA; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE P1; IBRITUMOMAB TIUXETAN; MIXED LINEAGE LEUKEMIA PROTEIN; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TIOGUANINE; TOSITUMOMAB I 131; TRANSCRIPTION FACTOR RUNX; VINCRISTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLADDER CANCER; BLADDER CARCINOMA; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RESEARCH; CANCER SURVIVAL; CHILD CARE; CHROMOSOMAL INSTABILITY; COLON CANCER; DNA DAMAGE; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; IONIZING RADIATION; KAPOSI SARCOMA; KIDNEY CANCER; LATENT PERIOD; LEUKEMIA; LIFESTYLE MODIFICATION; LUNG CANCER; MELANOMA; METASTASIS; MOLECULAR BIOLOGY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; POPULATION RESEARCH; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECOND CANCER; SEX DIFFERENCE; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LYMPHOMA, NON-HODGKIN; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; RISK FACTORS;

EID: 34548010100     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701447346     Document Type: Review

References (110)

1. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch
2. (2005) Cancer Facts and Figures 2005, American Cancer Society, Atlanta, Ga
3. Tward, J. D., Wendland, M. M., Shrieve, D. C., Szabo, A. and Gaffney, D. K. (2006) The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer, 107, pp. 108-115.
4. Travis, L. B., Curtis, R. E., Boice Jr, J. D. and Fraumeni Jr, J. F. (1989) Bladder cancer after chemotherapy for non-Hodgkin's lymphoma. N Engl J Med, 321, pp. 544-545.
5. Travis, L. B., Curtis, R. E., Boice Jr, J. D., Hankey, B. F. and Fraumeni Jr, J. F. (1991) Second cancers following non-Hodgkin's lymphoma. Cancer, 67, pp. 2002-2009.
6. Travis, L. B., Curtis, R. E., Glimelius, B., Holowaty, E., Van Leeuwen, F. E. and Lynch, C. F. (1993) Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst, 85, pp. 1932-1937.
7. Travis, L. B., Curtis, R. E., Glimelius, B., Holowaty, E. J., Van Leeuwen, F. E. and Lynch, C. F. (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst, 87, pp. 524-530.
8. Brennan, P., Coates, M., Armstrong, B., Colin, D. and Boffetta, P. (2000) Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia. Br J Cancer, 82, pp. 1344-1347.
9. Brennan, P., Scelo, G., Hemminki, K., Mellemkjaer, L., Tracey, E. and Andersen, A. (2005) Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer, 93, pp. 159-166.
10. Okines, A., Thomson, C. S., Radstone, C. R., Horsman, J. M. and Hancock, B. W. (2005) Second primary malignancies after treatment for malignant lymphoma. Br J Cancer, 93, pp. 418-424.
11. Mudie, N. Y., Swerdlow, A. J., Higgins, C. D., Smith, P., Qiao, Z. and Hancock, B. W. (2006) Risk of second malignancy after non-Hodgkin's lymphoma: A British Cohort Study. J Clin Oncol, 24, pp. 1568-1574.
12. Greene, M. H., Young, R. C., Merrill, J. M. and DeVita, V. T. (1983) Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res, 43, pp. 1891-1898.
13. Andre, M., Mounier, N., Leleu, X., Sonet, A., Brice, P. and Henry-Amar, M. (2004) Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: A GELA cohort study on 2837 patients. Blood, 103, pp. 1222-1228.
14. Armitage, J. O., Carbone, P. P., Connors, J. M., Levine, A., Bennett, J. M. and Kroll, S. (2003) Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol, 21, pp. 897-906.
15. Darrington, D. L., Vose, J. M., Anderson, J. R., Bierman, P. J., Bishop, M. R. and Chan, W. C. (1994) Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol, 12, pp. 2527-2534.
16. Lavey, R. S., Eby, N. L. and Prosnitz, L. R. (1990) Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer, 66, pp. 80-88.
17. Lenz, G., Dreyling, M., Schiegnitz, E., Haferlach, T., Hasford, J. and Unterhalt, M. (2004) Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol, 22, pp. 4926-4933.
18. Oddou, S., Vey, N., Viens, P., Bardou, V. J., Faucher, C. and Stoppa, A. M. (1998) Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: A report of six cases in a cohort of 171 patients from a single institution. Leuk Lymphoma, 31, pp. 187-194.
19. Pedersen-Bjergaard, J., Jonsson, V., Pedersen, M. and Hou-Jensen, K. (1995) Leiomyosarcoma of the urinary bladder after cyclophosphamide. J Clin Oncol, 13, pp. 532-533.
20. Stone, R. M., Neuberg, D., Soiffer, R., Takvorian, T., Whelan, M. and Rabinowe, S. N. (1994) Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol, 12, pp. 2535-2542.
21. Moertel, C. G. and Hagedorn, A. B. (1957) Leukemia or lymphoma and coexistent primary malignant lesions: A review of the literature and a study of 120 cases. Blood, 12, pp. 788-803.
22. Berg, J. W. (1967) The incidence of multiple primary cancers. I. Development of further cancers in patients with lymphomas, leukemias, and myeloma. J Natl Cancer Inst, 38, pp. 741-752.
23. Zarrabi, M. H. (1980) Association of non-Hodgkin's lymphoma (NHL) and second neoplasms. Semin Oncol, 7, pp. 340-351.
24. MacDougall, B. K., Weinerman, B. H. and Kemel, S. (1981) Second malignancies in non-Hodgkin's lymphoma. Cancer, 48, pp. 1299-1301.
25. Storm, H. H. and Prener, A. (1985) Second cancer following lymphatic and hematopoietic cancers in Denmark, 1943-80. Natl Cancer Inst Monogr, 68, pp. 389-409.
26. Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K. and Vardiman, J. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol, 17, pp. 3835-3849.
27. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage (1982) The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer, 49, pp. 2112-2135.
28. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma (1997) The Non-Hodgkin's Lymphoma Classification Project. Blood, 89, pp. 3909-3918.
29. A predictive model for aggressive non-Hodgkin's lymphoma (1993) The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med, 329, pp. 987-994.
30. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H. and Bron, D. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 333, pp. 1540-1545.
31. Pedersen-Bjergaard, J., Ersboll, J., Hansen, V. L., Sorensen, B. L., Christoffersen, K. and Hou-Jensen, K. (1988) Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med, 318, pp. 1028-1032.
32. Pedersen-Bjergaard, J., Ersboll, J., Sorensen, H. M., Keiding, N., Larsen, S. O. and Philip, P. (1985) Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med, 103, pp. 195-200.
33. Boice, J. D. (1981) Cancer following medical irradiation. Cancer, 47:5, pp. 1081-1090.
34. Boice Jr, J. D. (2001) Radiation and breast carcinogenesis. Med Pediatr Oncol, 36, pp. 508-513.
35. Travis, L. B., Weeks, J., Curtis, R. E., Chaffey, J. T., Stovall, M. and Banks, P. M. (1996) Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol, 14, pp. 565-571.
36. Pedersen-Bjergaard, J., Daugaard, G., Hansen, S. W., Philip, P., Larsen, S. O. and Rorth, M. (1991) Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet, 338, pp. 359-363.
37. Travis, L. B. (2006) The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev, 15, pp. 2020-2026.
38. Behrens, C., Travis, L. B., Wistuba II, Davis, S., Maitra, A. and Clarke, E. A. (2000) Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev, 9, pp. 1027-1035.
39. De Benedetti, V. M., Travis, L. B., Welsh, J. A., van Leeuwen, F. E., Stovall, M. and Clarke, E. A. (1996) p53 mutations in lung cancer following radiation therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev, 5, pp. 93-98.
40. Khan, M. A., Travis, L. B., Lynch, C. F., Soini, Y., Hruszkewycz, A. M. and Delgado, R. M. (1998) p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev, 7, pp. 397-403.
41. Leonard, D. G., Travis, L. B., Addya, K., Dores, G. M., Holowaty, E. J. and Bergfeldt, K. (2002) p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer. Clin Cancer Res, 8, pp. 973-985.
42. Allan, J. M. and Travis, L. B. (2005) Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer, 5, pp. 943-955.
43. Pedersen-Bjergaard, J., Philip, P., Larsen, S. O., Andersson, M., Daugaard, G. and Ersboll, J. (1993) Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia, 7, pp. 1975-1986.
44. Baldwin, E. L. and Osheroff, N. (2005) Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents, 5, pp. 363-372.
45. Kelly, L. M. and Gilliland, D. G. (2002) Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet, 3, pp. 179-198.
46. Orlandi, E., Lazzarino, M., Bernasconi, P., Astori, C. and Bernasconi, C. (1998) Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma. Haematologica, 83, pp. 758-759.
47. Larson, R. A., Wang, Y., Banerjee, M., Wiemels, J., Hartford, C. and Beau, M M Le (1999) Prevalence of the inactivating 609C->T polymorphism in the NAD(P)H:qUinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 94, pp. 803-807.
48. Naoe, T., Takeyama, K., Yokozawa, T., Kiyoi, H., Seto, M. and Uike, N. (2000) Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res, 6, pp. 4091-4095.
49. Allan, J. M., Wild, C. P., Rollinson, S., Willett, E. V., Moorman, A. V. and Dovey, G. J. (2001) Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA, 98, pp. 11592-11597.
50. Roboz, G. J., Bennett, J. M., Coleman, M., Ritchie, E. K., Furman, R. R. and Rossi, A. (2007) Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leuk Res
51. Halperin, E. C. (2006) Particle therapy and treatment of cancer. Lancet Oncol, 7, pp. 676-685.
52. Hall, E. (1988) Radiobiology for the Radiobiologist, JB Lippincott Co., Philadelphia
53. Aust, A. E. and Eveleigh, J. F. (1999) Mechanisms of DNA oxidation. Proc Soc Exp Biol Med, 222, pp. 246-252.
54. Hall, E. (2000) Radiobiology for the Radiobiologist, JB Lippincott Co., Philadelphia
55. Dong, C. and Hemminki, K. (2001) Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: A search for common mechanisms. Br J Cancer, 85, pp. 997-1005.
56. van Leeuwen, F. E., Klokman, W. J., Stovall, M., Dahler, E. C., Veer, M B van't and Noordijk, E. M. (2003) Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst, 95, pp. 971-980.
57. Travis, L. B., Hill, D. A., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E. and Holowaty, E. (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. Jama, 290, pp. 465-475.
58. Latz, D., Nassar, N. and Frank, R. (2004) Trofosfamide in the palliative treatment of cancer: A review of the literature. Onkologie, 27, pp. 572-576.
59. Gandhok, N. and Sartor, O. (2004) Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen. Urology, 64, pp. 807-809.
60. Patel, A. V., Rodriguez, C., Jacobs, E. J., Solomon, L., Thun, M. J. and Calle, E. E. (2005) Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomarkers Prev, 14, pp. 275-279.
61. Greenwald, P. (2005) Lifestyle and medical approaches to cancer prevention. Recent Results Cancer Res, 166, pp. 1-15.
62. Amling, C. L. (2004) The association between obesity and the progression of prostate and renal cell carcinoma. Urol Oncol, 22, pp. 478-484.
63. West, J. G., Qureshi, A., West, J. E., Chacon, M., Sutherland, M. L. and Haghighi, B. (2005) Risk of angiosarcoma following breast conservation: a clinical alert. Breast J, 11, pp. 115-123.
64. Rubino, C., Shamsaldin, A., Le, M. G., Labbe, M., Guinebretiere, J. M. and Chavaudra, J. (2005) Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat, 89, pp. 277-288.
65. Pothuri, B., Ramondetta, L., Martino, M., Alektiar, K., Eifel, P. J. and Deavers, M. T. (2003) Development of endometrial cancer after radiation treatment for cervical carcinoma. Obstet Gynecol, 101:5, pp. 941-945.
66. Moser, E. C., Noordijk, E. M., van Leeuwen, F. E., Baars, J. W., Thomas, J. and Carde, P. (2006) Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica, 91, pp. 1481-1488.
67. Travis, L. B., Curtis, R. E., Stovall, M., Holowaty, E. J., van, Leeuwen FE and Glimelius, B. (1994) Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst, 86, pp. 1450-1457.
68. Travis, L. B., Rabkin, C. S., Brown, L. M., Allan, J. M., Alter, B. P. and Ambrosone, C. B. (2006) Cancer survivorship-genetic susceptibility and second primary cancers: Research strategies and recommendations. J Natl Cancer Inst, 98, pp. 15-25.
69. Blume, K. G. (2002) Autologous or allogeneic hematopoietic cell transplantation for non-Hodgkin's lymphoma?. Ann Hematol, 81, pp. S9-S11.
70. Horwitz, S. M., Negrin, R. S., Blume, K. G., Breslin, S., Stuart, M. J. and Stockerl-Goldstein, K. E. (2004) Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood, 103, pp. 777-783.
71. Nademanee, A., Forman, S., Molina, A., Fung, H., Smith, D. and Dagis, A. (2005) A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood, 106, pp. 2896-2902.
72. Vose, J. M., Bierman, P. J., Enke, C., Hankins, J., Bociek, G. and Lynch, J. C. (2005) Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 461-467.
73. Khouri, I. F. (2006) Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program, pp. 390-397.
74. Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G. and Lowsky, R. (2006) High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant, 12, pp. 703-711.
75. Maloney, D. G. (2003) Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma. Leuk Lymphoma, 44, pp. S99-S105.
76. Bhatia, S., Ramsay, N. K., Steinbuch, M., Dusenbery, K. E., Shapiro, R. S. and Weisdorf, D. J. (1996) Malignant neoplasms following bone marrow transplantation. Blood, 87, pp. 3633-3639.
77. Deeg, H. J. and Socie, G. (1998) Malignancies after hematopoietic stem cell transplantation: Many questions, some answers. Blood, 91, pp. 1833-1844.
78. Kolb, H. J., Socie, G., Duell, T., Van Lint, M. T., Tichelli, A. and Apperley, J. F. (1999) Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med, 131, pp. 738-744.
79. Lowsky, R., Lipton, J., Fyles, G., Minden, M., Meharchand, J. and Tejpar, I. (1994) Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol, 12, pp. 2187-2192.
80. Witherspoon, R. P., Fisher, L. D., Schoch, G., Martin, P., Sullivan, K. M. and Sanders, J. (1989) Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med, 321, pp. 784-789.
81. Rizzo, J., Curtis, R. and Deeg, H. J. (2001) Long-term follow-up of allogeneic blood stem cell and bone marrow transplantation: A collaborative study of EBMT and IBMTR. Blood, 98, p. 774A.
82. Curtis, R. E., Rowlings, P. A., Deeg, H. J., Shriner, D. A., Socie, G. and Travis, L. B. (1997) Solid cancers after bone marrow transplantation. N Engl J Med, 336, pp. 897-904.
83. de Vathaire, F., Francois, P., Hill, C., Schweisguth, O., Rodary, C. and Sarrazin, D. (1989) Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer, 59, pp. 792-796.
84. Garwicz, S., Anderson, H., Olsen, J. H., Dollner, H., Hertz, H. and Jonmundsson, G. (2000) Second malignant neoplasms after cancer in childhood and adolescence: A population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer, 88, pp. 672-678.
85. Neglia, J. P., Friedman, D. L., Yasui, Y., Mertens, A. C., Hammond, S. and Stovall, M. (2001) Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst, 93, pp. 618-629.
86. Leung, W., Sandlund, J. T., Hudson, M. M., Zhou, Y., Hancock, M. L. and Zhu, Y. (2001) Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer, 92, pp. 1959-1966.
87. de Vathaire, F., Hardiman, C., Shamsaldin, A., Campbell, S., Grimaud, E. and Hawkins, M. (1999) Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med, 159, pp. 2713-2719.
88. Neglia, J. P., Meadows, A. T., Robison, L. L., Kim, T. H., Newton, W. A. and Ruymann, F. B. (1991) Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med, 325, pp. 1330-1336.
89. Pottern, L. M., Kaplan, M. M., Larsen, P. R., Silva, J. E., Koenig, R. J. and Lubin, J. H. (1990) Thyroid nodularity after childhood irradiation for lymphoid hyperplasia: A comparison of questionnaire and clinical findings. J Clin Epidemiol, 43, pp. 449-460.
90. Ron, E., Modan, B., Preston, D., Alfandary, E., Stovall, M. and Boice Jr, J. D. (1989) Thyroid neoplasia following low-dose radiation in childhood. Radiat Res, 120, pp. 516-531.
91. Beaty III, O., Hudson, M. M., Greenwald, C., Luo, X., Fang, L. and Wilimas, J. A. (1995) Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol, 13, pp. 603-609.
92. Tarbell, N. J., Gelber, R. D., Weinstein, H. J. and Mauch, P. (1993) Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood. Lancet, 341, pp. 1428-1432.
93. Bhatia, S., Robison, L. L., Oberlin, O., Greenberg, M., Bunin, G. and Fossati-Bellani, F. (1996) Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med, 334, pp. 745-751.
94. Hancock, S. L., Tucker, M. A. and Hoppe, R. T. (1993) Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst, 85, pp. 25-31.
95. Hawkins, M. M., Wilson, L. M., Burton, H. S., Potok, M. H., Winter, D. L. and Marsden, H. B. (1996) Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst, 88, pp. 270-278.
96. Vu, B Le, de Vathaire, F., Shamsaldin, A., Hawkins, M. M., Grimaud, E. and Hardiman, C. (1998) Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer, 77, pp. 370-377.
97. Tucker, M. A., D'Angio, G. J., Boice Jr, J. D., Strong, L. C., Li, F. P. and Stovall, M. (1987) Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med, 317, pp. 588-593.
98. Gomez, G. A., Aggarwal, K. K. and Han, T. (1982) Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma. Cancer, 50, pp. 2285-2288.
99. Meadows, A. T., Baum, E., Fossati-Bellani, F., Green, D., Jenkin, R. D. and Marsden, B. (1985) Second malignant neoplasms in children: An update from the Late Effects Study Group. J Clin Oncol, 3, pp. 532-538.
100. Pillon, M., Di, Tullio MT, Garaventa, A., Cesaro, S., Putti, M. C. and Favre, C. (2004) Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer, 101, pp. 385-394.
101. Sandoval, C., Pui, C. H., Bowman, L. C., Heaton, D., Hurwitz, C. A. and Raimondi, S. C. (1993) Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol, 11, pp. 1039-1045.
102. Pyatt, D. W., Hays, S. M. and Cushing, C. A. (2005) Do children have increased susceptibility for developing secondary acute myelogenous leukemia?. Chem Biol Interact, 153154, pp. 223-229.
103. Pui, C. H., Ribeiro, R. C., Hancock, M. L., Rivera, G. K., Evans, W. E. and Raimondi, S. C. (1991) Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med, 325, pp. 1682-1687.
104. Smith, M. A., Rubinstein, L., Anderson, J. R., Arthur, D., Catalano, P. J. and Freidlin, B. (1999) Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol, 17, pp. 569-577.
105. Sugita, K., Furukawa, T., Tsuchida, M., Okawa, Y., Nakazawa, S. and Akatsuka, J. (1993) High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma. Am J Pediatr Hematol Oncol, 15, pp. 99-104.
106. Smith, M. A., Rubinstein, L., Cazenave, L., Ungerleider, R. S., Maurer, H. M. and Heyn, R. (1993) Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Natl Cancer Inst, 85, pp. 554-558.
107. German, J. (1997) Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet, 93, pp. 100-106.
108. Poppe, B., Van Limbergen, H., Van Roy, N., Vandecruys, E., De Paepe, A. and Benoit, Y. (2001) Chromosomal aberrations in Bloom syndrome patients with myeloid malignancies. Cancer Genet Cytogenet, 128, pp. 39-42.
109. Makis, A., Polychronopoulou, S. and Haidas, S. (2004) Osteosarcoma as a second tumor after treatment for primary non-Hodgkin's lymphoma in a child with ataxia-telangiectasia: Presentation of a case and review of possible pathogenetic mechanisms. J Pediatr Hematol Oncol, 26, pp. 444-446.
110. Overberg-Schmidt, U., Wegner, R. D., Baumgarten, E., Gunther, A., Ebell, W. and Stein, H. (1994) Low-grade non-Hodgkin's lymphoma after high-grade non-Hodgkin's lymphoma in a child with ataxia telangiectasia. Cancer, 73, pp. 1522-1525.